The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model

Chemotherapy-resistant osteosarcoma is a recalcitrant disease. It is a frequent cause of death to the patients who are usually adolescent or young adults. The goal of the present study was to determine the efficacy of the combination of olaratumab (OLA), doxorubicin (DOX), and cisplatinum (CDDP) on...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Takashi, Sugisawa, Norihiko, Miyake, Kentaro, Oshiro, Hiromichi, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624322/
https://www.ncbi.nlm.nih.gov/pubmed/31299622
http://dx.doi.org/10.1016/j.tranon.2019.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624322/
https://www.ncbi.nlm.nih.gov/pubmed/31299622
http://dx.doi.org/10.1016/j.tranon.2019.06.002

Ejemplares similares